| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | GLYTR THERAPEUTICS, INC. | 5151 CALIFORNIA AVE | IRVINE | CA | 92617-3206 | ORANGE | USA | R42CA285234 | Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy | 000 | 1 | NIH | 2/3/2025 | $0 |
| | 2025 | 2021 | GLYTR THERAPEUTICS, INC. | 5151 CALIFORNIA AVE | IRVINE | CA | 92617-3206 | ORANGE | USA | R41CA261408 | Cancer Immunotherapy Targeting Tn Antigen | 000 | 1 | NIH | 12/9/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $908,910 ) |
| | 2024 | 2024 | GLYTR THERAPEUTICS, INC. | 5151 CALIFORNIA AVE | IRVINE | CA | 92617-3206 | ORANGE | USA | R42CA285234 | Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy | 001 | 2 | NIH | 8/29/2024 | $908,910 |
| | 2024 | 2023 | GLYTR THERAPEUTICS, INC. | 5151 CALIFORNIA AVE | IRVINE | CA | 92617-3206 | ORANGE | USA | R42CA285234 | Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy | 000 | 1 | NIH | 10/12/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $400,000 ) |
| | 2023 | 2023 | GLYTR THERAPEUTICS, INC. | 5151 CALIFORNIA AVE | IRVINE | CA | 92617-3206 | ORANGE | USA | R42CA285234 | Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy | 000 | 1 | NIH | 9/20/2023 | $400,000 |
| | 2023 | 2021 | GLYTR THERAPEUTICS, INC. | 5151 CALIFORNIA AVE | IRVINE | CA | 92617-3206 | ORANGE | USA | R41CA261408 | Cancer Immunotherapy Targeting Tn Antigen | 000 | 1 | NIH | 8/23/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2018 | GLYTR THERAPEUTICS, INC. | 5151 CALIFORNIA AVE STE 150 | IRVINE | CA | 92617-3206 | ORANGE | USA | R41CA233111 | O-Glycan-dependent Immunotherapy for Cancer | 000 | 1 | NIH | 2/2/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $398,178 ) |
| | 2021 | 2021 | GLYTR THERAPEUTICS, INC. | 5151 CALIFORNIA AVE STE 150 | IRVINE | CA | 92617-3206 | ORANGE | USA | R41CA261408 | Cancer Immunotherapy Targeting Tn Antigen | 000 | 1 | NIH | 7/28/2021 | $398,178 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | GLYTR THERAPEUTICS, INC. | 5151 CALIFORNIA AVE STE 150 | IRVINE | CA | 92617-3206 | ORANGE | USA | R41CA233111 | O-Glycan-dependent Immunotherapy for Cancer | 001 | 1 | NIH | 7/15/2020 | $0 |
| | 2020 | 2018 | GLYTR THERAPEUTICS, INC. | 5151 CALIFORNIA AVE STE 150 | IRVINE | CA | 92617-3206 | ORANGE | USA | R41CA233111 | O-Glycan-dependent Immunotherapy for Cancer | 000 | 1 | NIH | 7/15/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $2,084 ) |
| | 2019 | 2019 | GLYTR THERAPEUTICS, INC. | 5151 CALIFORNIA AVE STE 150 | IRVINE | CA | 92617-3206 | ORANGE | USA | R41CA233111 | O-Glycan-dependent Immunotherapy for Cancer | 001 | 1 | NIH | 8/14/2019 | $2,084 |
| | 2019 | 2018 | GLYTR THERAPEUTICS, INC. | 5151 CALIFORNIA AVE STE 150 | IRVINE | CA | 92617-3206 | ORANGE | USA | R41CA233111 | O-Glycan-dependent Immunotherapy for Cancer | 000 | 1 | NIH | 3/4/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $298,530 ) |
| | 2018 | 2018 | GLYTR THERAPEUTICS, INC. | 5151 CALIFORNIA AVE STE 150 | IRVINE | CA | 92617-3206 | ORANGE | USA | R41CA233111 | O-Glycan-dependent Immunotherapy for Cancer | 000 | 1 | NIH | 9/18/2018 | $298,530 |
|
|
